Maastricht University Medical Centre (MUMC)

Maastricht 6229HX

0 studies enrolling now · 2 studies all time

What they study most

HER2+ Metastatic Breast Cancer (MBC), Non-small Cell Lung Cancer

Studies at this site

• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients — Running, not enrolling
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed